Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com - Piper Sandler initiated coverage on Janux Therapeutics (NASDAQ:JANX) with an Overweight rating and a price target of $42.00 on Tuesday. The target represents significant upside from the current price of $25.53, though InvestingPro analysis indicates the stock is currently trading above its Fair Value.
The research firm’s decision comes after investor sentiment toward Janux has weakened throughout 2025, despite highly positive reception to the company’s JANX007 clinical data in metastatic castration-resistant prostate cancer (mCRPC) in December 2024.
Piper Sandler noted that the recent stock pullback followed the emergence of competitor clinical data and Janux’s announcement of the completion of JANX007 dose escalation.
The firm views JANX007 as a differentiated, potentially best-in-class program in mCRPC treatment, positioning the current stock price as an attractive entry point for investors.
Piper Sandler expressed optimism about Janux’s prospects ahead of the clinical update expected later this year.
In other recent news, Janux Therapeutics held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on. The meeting resulted in the election of three Class I directors—David Campbell, Ph.D., Ron Barrett, Ph.D., and Winston Kung—who will serve until the 2028 Annual Meeting. Additionally, stockholders ratified the company’s independent registered public accounting firm and approved executive compensation. There was also a decision on the frequency of future stockholder votes on executive pay. In another development, Raymond (NSE:RYMD) James initiated coverage on Janux Therapeutics with an Outperform rating and set a price target of $65.00. The firm highlighted promising preliminary results for JANX007, a therapy for metastatic castration-resistant prostate cancer, noting its compelling efficacy at higher doses in third-line and beyond patients. These developments reflect ongoing strategic and operational activities at Janux Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.